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Abstract 24!
In striated muscle, EPA and DHA have differential effects on the metabolism of glucose and 25!
differential effects on the metabolism of protein. We have shown that, despite similar incorporation, 26!
treatment of C2C12 myotubes (CM) with EPA but not DHA improves glucose uptake and protein 27!
accretion. We hypothesized that these differential effects of EPA and DHA may be due to divergent 28!
shifts in lipidomic profiles leading to altered proteomic profiles. We therefore carried out an 29!
assessment on the impact of treating CM with EPA and DHA on lipidomic and proteomic profiles. 30!
FAME analysis revealed that both EPA and DHA led to similar but substantial changes in fatty acid 31!
profiles with the exception of arachidonic acid, which was decreased only by DHA, and DPA, which 32!
was increased only by EPA treatment. Global lipidomic analysis showed that EPA and DHA induced 33!
large alterations in the cellular lipid profiles and in particular, the phospholipid classes. Subsequent 34!
targeted analysis confirmed that the most differentially regulated species were phosphatidylcholines 35!
and phosphatidylethanolamines containing long chain fatty acids with 5 (EPA treatment) or 6 (DHA 36!
treatment) double bonds. As these are typically membrane associated lipid species we hypothesized 37!
that these treatments differentially altered the membrane-associated proteome. SILAC based 38!
proteomics of the membrane fraction revealed significant divergence in the effects of EPA and DHA 39!
on the membrane associated proteome. We conclude that the EPA specific increase in polyunsaturated 40!
long chain fatty acids in the phospholipid fraction is associated with an altered membrane associated 41!
proteome and these may be critical events in the metabolic remodelling induced by EPA treatment.       42!
Keywords: cell signalling, fish oil, fatty acid, insulin, lipidomics, lipids 43!
  44!
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Introduction 45!
Fatty acids play an important role in skeletal muscle metabolism, not only as substrates for oxidative 46!
phosphorylation or vital structural components of membranes but also as regulators of enzyme 47!
activities and signalling molecules (8). Furthermore, dysfunctions in the control of fatty acid 48!
metabolism can be an important factor in the aetiology of conditions such as insulin resistance and 49!
muscle atrophy (8). The lipid composition of skeletal muscle undergoes constant fluctuations and is 50!
reflective of dietary fat intake (6). There is strong evidence to suggest that the enrichment of skeletal 51!
muscle with omega-3 (n-3) fatty acids may have therapeutic benefits on muscle metabolism and 52!
function (14). Oral n-3 supplementation above the Reference Dietary Intake is known to result in 53!
significant incorporation of n-3 fatty acids into the skeletal muscle lipid pool (6, 13, 30).  54!
Several n-3 supplementation studies in humans have observed beneficial effects ranging from an 55!
increased sensitivity to anabolic stimuli (43, 44) and muscle function (40, 45).  Eight weeks n-3 56!
supplementation improved the muscle protein synthetic response (MPS) to a hyperinsulinaemic amino 57!
acid infusion in both young (44) and elderly individuals (43). Furthermore, when taken alongside a 58!
resistance based exercise programme (12, 40) or in the absence of any strength training (45) n-3 fatty 59!
acids enhance strength and or physical function in the elderly. Concurrent with anabolic properties, n-60!
3 FAs also display anti-catabolic effects. n-3 supplementation prevented muscle mass losses in burned 61!
guinea pigs (5) and protected against muscle mass loss during anti-neoplastic therapy in cancer 62!
patients (34). However, when combined in systematic reviews do not always show a beneficial effect 63!
on muscle mass during cancer treatment (39). Moreover n-3 FAs attenuated soleus atrophy in rodents 64!
that underwent 10 days of hind limb immobilization (55).  65!
As well as effects on muscle protein metabolism there is building evidence to suggest that n-3 fatty 66!
acids may also modulate glucose metabolism. Current meta-analyses detect a neutral or small effect of 67!
n-3 FAs on measures of insulin sensitivity (4). However, there are several studies across a range of 68!
models utilizing higher doses of n-3s which support a role for n-3s in improving muscle mitochondrial 69!
function and glucose metabolism (23, 28, 35, 37, 47, 48).  For instance, replacing 3.4% of the Kcals 70!
! 4!
with n-3 fatty acids on a high fat diet protects mice against declines in glucose tolerance during a 10-71!
week high fat diet despite similar increases in body weight compared to high fat alone (28). Whereas 72!
supplementation studies in humans have not demonstrated a consensus (4),  an interesting lipid 73!
infusion trial has shown n-3 fatty acids to be bioactive in humans with respect to glucose metabolism 74!
(46). More specifically, the addition of n-3 fatty acids to a lipid infusion of n-6 fatty acids attenuated 75!
the decline in insulin stimulated glucose disposal caused by n-6 infusion alone suggesting that the n-3 76!
fatty acids have a protective effect on glucose metabolism in the presence of an n-6 overload (46).  77!
Fish oil and n-3 supplements are a heterogeneous mixture of fatty acids of which eicosapentaenoic 78!
acid (EPA, 20:5) and docosahexaenoic acid (DHA 22:6) are thought to be the most biologically 79!
active. Due to many studies using a combination of EPA and DHA and varying ratios of each fatty 80!
acid it is difficult to assert whether EPA or DHA alone is causing the observed effects or if EPA and 81!
DHA work synergistically or antagonistically for that matter.  The molecular mechanisms of n-3 82!
action are still poorly understood. Work from Olefsky’s lab suggests that GPR120 acts as a general n-83!
3 receptor in macrophages and adipocytes that, when activated by n-3 fatty acids leads to increases in 84!
whole body insulin sensitivity by reducing inflammation (37).  EPA has also been shown to 85!
antagonise the action of TNFα on C2C12 myotube formation in a manner partially dependent on 86!
PPARγ (29). Additionally, EPA reduces the activation of Nuclear Factor-κappa Beta (NF-Kb) leading 87!
to a reduction in Muscle RING finger protein-1 (Murf-1) signalling, an important mediator of muscle 88!
atrophy in cultured myotubes (22). Furthermore, a follow up study employing both EPA and DHA 89!
demonstrated that DHA was more efficient in this mechanism than EPA (52). However, EPA has 90!
been shown to improve metabolic flexibility in response to changing substrate availabilities (21). EPA 91!
has also previously been shown to improve both basal and insulin stimulated glucose uptake in 92!
cultured myotubes (1). However, it remains to be seen whether DHA similarly improves glucose 93!
uptake in skeletal muscle.  Despite the numerous similar intracellular effects and similar structure, 94!
EPA and DHA may have divergent physiological effects in skeletal muscle.  EPA improves skeletal 95!
muscle protein metabolism while DHA has a non-significant effect (24). In other striated muscle 96!
models such as cardiomyocytes, EPA but not DHA increases glucose and fatty acid uptake despite 97!
! 5!
similar effects on cell signalling (18).  In plasma both EPA and DHA reduced triacylglycerol (TAG) 98!
but only DHA modulates HDL (high density lipoprotein) and LDL (low density lipoprotein) particle 99!
size (53). Collectively these data suggest that in certain contexts, EPA and DHA can have differential 100!
biological effects. 101!
The molecular mechanisms underpinning the divergent physiological effects of EPA vs DHA are 102!
currently under explored. However, differential remodelling of the lipid profile may partially explain 103!
the divergent physiological response observed between EPA and DHA. Currently studies attempting 104!
to address how n-3 fatty acids affect the lipidomic profile of skeletal muscle are limited. As expected 105!
n-3 intake leads to incorporation into the lipid pool of multiple tissues i.e. plasma, muscle, adipose 106!
tissue and liver with a significant proportion being directed towards phospholipid pools (7, 27, 30, 42-107!
44).  This incorporation is not limited to the plasma membrane and is also incorporated into 108!
subcellular organelles such as mitochondria (20). It is hypothesized that a primary driver of the effects 109!
of EPA and DHA is the displacement of arachidonic acid (AA) from membranes with studies from a 110!
range of models supporting this (27, 32, 42) while some in vivo human studies observe no change in 111!
total AA in the skeletal muscle lipid pool (30). However, this does not discount the possibility that 112!
AA might be displaced from specific lipid fractions. Multiple human studies have assessed the impact 113!
of n-3 supplementation on skeletal muscle phospholipid pool however the use of a heterogeneous mix 114!
of n-3 fatty acids precludes the ability to detect the isolated effects of EPA vs DHA on lipid profiles 115!
(6, 13, 30).  Furthermore, into which skeletal muscle phospholipid fractions EPA and DHA are 116!
incorporated are poorly understood. In plasma phospholipids EPA and DHA induce a similar lipid 117!
profile yet EPA increased docosapentanoic acid (DPA 22:5 n-3) and a differential but non-significant 118!
increase in stearate acid (SA 18:0) (31). In smooth muscle cell phospholipids both EPA and DHA are 119!
heavily incorporated into the phosphatidylcholine (PC) fraction but EPA is divergently incorporated 120!
into the phosphatidylinositol (PI) and phosphatidylserine (PS) fraction while DHA is incorporated 121!
into the phosphatidylethanolamine (PE) fraction (33).  122!
One of the main cellular fates for fatty acids is incorporation into complex lipid species and so it 123!
seems logical to hypothesize that the differential action of EPA and DHA may be due to differential 124!
! 6!
effects on the cellular lipidome. To date no study has characterised the impact of EPA and DHA 125!
individually on lipidomic profiles in skeletal muscle. In this manuscript we demonstrate that the C2C12 126!
cell line acts as a model in which EPA and DHA have differential effects on metabolism. We 127!
followed these experiments by an extensive assessment of lipid changes hypothesizing that the 128!
divergent effects of EPA and DHA are associated with differential regulation of the skeletal muscle 129!
lipidome. The lipidomic profiling indicated that multiple membrane associated lipid species were 130!
differentially altered by EPA and DHA treatments. We therefore hypothesized that the lipidomic 131!
remodelling would be associated with remodelling of the membrane-associated proteome. SILAC 132!
based proteomics of the membrane fraction indicated EPA and DHA differentially regulate the 133!
membrane associated proteome. Therefore, the effects of EPA may be due to membrane associated 134!
proteomic remodelling secondary to lipidomic remodelling of the membrane-associated lipids. 135!
  136!
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Materials and methods 137!
Materials 138!
All plasticware for tissue culture was purchased from fisher scientific (UK). Tissue culture media and 139!
sera were purchased from Invitrogen. Fatty acids EPA and DHA (>99%, liquid form) were purchased 140!
from Sigma Aldrich (Dorset, UK). H32-DG was purchased from Hartman Analytic. All solvents were 141!
LC-MS grade (Fisher Scientific, Loughborough, UK). 142!
Cell culture 143!
C2C12 myoblasts were grown in Dulbecco’s Modified Eagle Medium (DMEM) containing 20% fetal 144!
bovine serum and 1% penicillin/streptomycin and incubated at 37°C and 5% C02. Myoblasts were 145!
maintained at ~60% confluence. Differentiation was induced once confluence reached 80-90% by 146!
changing the media to differentiation media (DMEM supplemented with 2% horse serum and 1% 147!
Penicillin/Streptomycin) for 72 hours. Following 72 hours differentiation cells were treated with 50 148!
µM EPA or 50 µM DHA pre-bound to 2% fatty acid free BSA for 72 hours before collection. As a 149!
control cells were treated with 2% fatty acid free (FAF) BSA for 72 hours before collection. Fatty 150!
acids were conjugated to 2% fatty acid free BSA in DM by constant agitation for 1 hour at 37°C. 151!
Following treatment cell pellets were collected following 3 washes in 2% FAF BSA in PBS and 152!
centrifuged at 800 rpm for 4 minutes, excess liquid was removed and pellets were frozen in liquid 153!
nitrogen and stored at -80°C until further analysis. 154!
FAME analysis 155!
Total lipids were extracted by homogenising in 20 volumes of chloroform/methanol (2:1 v/v). Total 156!
lipids were prepared according to the method of Folch et al. (17) and non-lipid impurities were 157!
removed by washing with 0.88% (w/v) KCl. The weight of lipids was determined gravimetrically 158!
after evaporation of solvent and overnight desiccation under vacuum. Fatty acid methyl esters 159!
(FAME) were prepared by acid-catalysed transesterification of total lipids according to the method of 160!
Christie et al. (35). Extraction and purification of FAME was performed as described by Ghioni et al. 161!
(36). FAME were separated by gas-liquid chromatography using a ThermoFisher Trace GC 2000 162!
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(ThermoFisher, Hemel Hempstead, UK) equipped with a fused silica capillary column (ZBWax, 60m 163!
x 0.25 µm x 0.25 mm i.d.; Phenomenex, Macclesfield, UK) with hydrogen as carrier gas and using 164!
on-column injection. The temperature gradient was form 50 to 150oC at 40oC/min and then to 195oC 165!
at 1.5oC/min and finally to 220oC at 2oC/min. Individual methyl esters were identified by reference to 166!
published data (Ackman, 1980). Data were collected and processed using the Chromcard for 167!
Windows (version 2.00) computer package (Thermoquest Italia S.p.A., Milan, Italy). All experiments 168!
were carried in duplicate from 4 independent experiments. Data were represented as fold change from 169!
the respective BSA control condition, logged to log2 and significance was determined by t-test and 170!
corrected for false discovery rate.   171!
Global lipidomic analysis of C2C12 myotubes 172!
Lipid extraction was performed according to the method described above. The lipids were analysed by 173!
liquid chromatography-mass spectrometry (LC-MS) using a Thermo Exactive Orbitrap mass 174!
spectrometer (Thermo Scientific, Hemel Hempstead, UK), equipped with a heated electrospray 175!
ionization probe and coupled to a Thermo Accela 1250 UHPLC system. All samples were analysed in 176!
both positive and negative ion mode over the mass to charge (m/z) range 200-2000. The lipids were 177!
separated on to a Thermo Hypersil Gold C18 column (1.9 µm, 2.1mm x 100 mm,). Mobile phase A 178!
consisted of water containing 10 mM ammonium formate and 0.1% (v/v) formic acid. Mobile phase B 179!
consisted of 90:10 isopropanol/acetonitrile containing 10 mM ammonium formate and 0.1% (v/v) 180!
formic acid. The initial conditions for analysis were 65%A/35%B. The percentage of mobile phase B 181!
was increased to 100% over 10 min and held for 7 minutes before re-equilibration with the starting 182!
conditions for 4 minutes. The raw LC-MS data were processed with Progenesis QI v2.0 software 183!
(Non-linear Dynamics, Newcastle, UK) and searched against LIPID MAPS (www.lipidmaps.org) and 184!
the Human Metabolome Database (http://www.hmdb.ca/) for identification. All experiments were 185!
carried out in duplicate from three independent experiments. 186!
 187!
Phospholipid profiling of C2C12 myotubes  188!
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In order to assess the incorporation of EPA and DHA into cellular phospholipids the lipid extracts 189!
from C2C12 myotubes were analysed by electrospray ionisation-tandem mass spectrometry (ESI-190!
MS/MS).  All analyses were performed using a Thermo TSQ Quantum Ultra triple quadrupole mass 191!
spectrometer equipped with a heated electrospray ionization probe. Samples were directly infused into 192!
the ion source at a flow rate of 5 µL/min. Phosphatidylcholine, lysophosphatidylcholine and 193!
sphingomyelin species were identified by precursor scanning for mass to charge ratio (m/z) 184 in 194!
positive ion mode.  Phosphatidylethanolamine and lysophosphatidylethanolamine species were 195!
identified by neutral loss scanning for m/z 141 in positive ion mode. Phosphatidylserine species were 196!
identified by neutral loss scanning for m/z 87 in negative ion mode. Phosphatidylinositol species were 197!
identified by precursor scanning for m/z 241 in negative ion mode. The data were expressed as a 198!
percentage composition of the relevant phospholipid fraction. 199!
 200!
Glucose uptake 201!
C2C12 myotubes, were exposed to 50µM EPA or 50µM DHA pre-bound to 2% fatty acid free BSA 202!
or 2% fatty acid free BSA as a control for 48 h before a 2 h serum-starve. Following the 2 h serum 203!
starve cells were exposed to insulin (100 nmol/l) or vehicle control for 30 mins. Myotubes were 204!
incubated (12 min) with 10 µmol/l 2-deoxy-D-[3 H]glucose (2DG; 24.4 kBq/ml; Hartman Analytic) at 205!
20°C. Non-specific uptake was determined using 10 µmol/l cytochalasin B (Sigma–Aldrich). After 206!
lysis, cell-associated radioactivity was measured (Beckman, High Wycombe, UK; LS 6000IC 207!
scintillation counter), and protein was quantified using the Bradford reagent. Data represented are the 208!
average of 6 independent experiments carried out in duplicate. 209!
Mitochondrial function 210!
C2C12 myotubes, were exposed to 50µM EPA or 50µM DHA pre-bound to 2% fatty acid free BSA 211!
or 2% fatty acid free BSA as a control for 48 h. Following 48 h in the respective treatments cells were 212!
degassed and exposed to a mito-stress test in the Seahorse cellular respiration analyser as previously 213!
described (16). 214!
! 10!
Muscle protein synthesis and muscle protein breakdown 215!
Protein!degradation!was!assessed!by!the!quantification!of!the!released!LA[2,4,3H]!phenylalanine!into!216!
the! culture! media.! Following! 4! days! of! differentiation! myotubes! were! incubated! with! medium!217!
containing!2.5!µCi!LA[2,4,3H]!phenylalanine/ml!and!the!label!was!maintained!for!24!hours!in!order!to!218!
label!long!lived!proteins.!Following!the!pulse!the!cells!were!washed!2x!in!PBS!and!incubated!in!cold!219!
chase!media! (DMEM! +! 2mM! LAphenylalanine)! for! 3! hours! to! allow! for! degradation! of! short! lived!220!
proteins.!Myotubes!were!then!treated!with!either!50!µM!EPA/DHA!bound!to!2%!FAFABSA!or!2%!FAFA221!
BSA!alone! for!24!hrs.! Following! treatment!an!aliquot!of! the!media!was! removed!and! radioactivity!222!
released! was! assessed! by! scintillation! counting.! The! remaining! myotubes! were! then! thoroughly!223!
washed!with!ice!cold!saline!(0.9%)!and!lysed!with!50mM!NaOH!+!1%!SDS!for!a!minimum!of!30!mins!224!
at! room! temperature.! Residual! radioactivity! in! cell! lysates! was! then! assessed! by! scintillation!225!
counting.!Total!radioactivity!was!calculated!as!the!sum!of!the!LA[2,4,3H]!phenylalanine!released!into!226!
the!media!and!the!residual!cell!retained!LA[2,4,3H]!phenylalanine.!Protein!breakdown!is!presented!as!227!
the!fraction!of!the!total!incorporated!LA[2,4,3H]!phenylalanine!released!into!the!media.!228!
!229!
Basal!protein! synthesis!was!assessed!by! the! incorporation!of! LA[2,4,3H]!phenyalalnine! into!peptide!230!
chains.!Following!differentiation,!myotubes!were!treated!with!either!50!µM!EPA/DHA!bound!to!2%!231!
FAFABSA!or!2%!FAFABSA!alone!for!24!hrs.!At!the!end!of!the!treatment!period!the!media!was!removed!232!
and! DMEM! containing! 1µCi! LA[2,43H]! phenylalanine! (0.5! µCi/ml)! was! added! for! 180! mins.! The!233!
reaction!was!stopped!by!2x!washes!in!ice!cold!saline!(0.9%)!before!3x!washes!with!Tricholoroacetic!234!
acid! (TCA)! (10%)! to! remove!any!unincorporated! tracer.!Residual!TCA!was! then!removed!by! rinsing!235!
cells!with!methanol!and!plates!left!to!dry.!!Myotubes!were!then!lysed!in!50mM!NaOH!+!1%!SDS!for!a!236!
minimum! of! 30! minutes.! An! aliquot! was! collected! for! liquid! scintillation! counting! to! assess! 3H!237!
incorporation!into!proteins!and!the!remaining!lysate!was!used!to!determine!protein!content!by!the!238!
DC!protein!assay.!Protein!synthesis!is!presented!as!counts!per!minute/µg!of!protein. 239!
 240!
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Protein content 241!
Protein content following 72 h treatment with 50µM EPA or 50µM DHA pre-bound to 2% fatty acid 242!
free BSA or 2% fatty acid free BSA as a control was determined by multiplying the concentration of 243!
the supernatant [as determined using the bicinchoninic acid protein assay according to the 244!
manufacturer’s instructions (Sigma Aldrich, UK)] by the total volume of supernatant collected from a 245!
6 well plate. Data are representative of 5 independent experiments carried out in triplicate. 246!
 247!
Cell processing  248!
Cell lysates were collected from 6 well plates by scraping on ice in RIPA buffer [50 mmol/l Tris·HCl 249!
pH 7.5, 50 mmol/l NaF, 500 mmol/l NaCl, 1 mmol/l sodium vanadate, 1 mmol/l EDTA, 1% (vol/vol) 250!
Triton X-100, 5 mmol/l sodium pyrophosphate, 0.27 mmol/l sucrose, and 0.1% (vol/vol) 2-251!
mercaptoethanol and Complete protease inhibitor cocktail (Roche)] followed by snap freezing on 252!
liquid nitrogen. For preparation for western blotting samples were thawed and debris was removed by 253!
centrifugation at 4°C for 15 min at 13,000 g. The supernatant was then removed, and protein 254!
concentration was determined using the bicinchoninic acid protein assay according to the 255!
manufacturer’s instructions (Sigma Aldrich, UK).  256!
 257!
Western blotting 258!
For WB, 100µg of supernatant was made up in Lamelli sample buffer, and 15 µg of total protein was 259!
loaded per well and run at 150 V for 1 h 15 min. Proteins were then transferred onto Whatman 260!
Immunobilon Nitrocellulose membranes (Fisher Scientific, Loughborough, UK) at 30 V overnight on 261!
ice. Membranes were blocked in 3% BSA-Tris-buffered saline (containing vol/vol 0.1% Tween 20) 262!
for 1 h at room temperature, followed by incubation in primary antibodies [PKBthr308 (#2965) or 263!
total PKB (#4691) GLUT 1(Santa cruz, sc-7903), GLUT4 (#2213S), Hexokinase 1 (#2204S), 264!
Hexokinase 2 (#2867S), Mito profile (abcam, #ab110413) (New England Biolabs unless stated)] at 265!
4°C overnight. Membranes underwent three 5 min washes in TBST followed by incubation in the 266!
appropriate secondary antibodies [secondary horseradish peroxidase conjugated antibody was 267!
purchased from ABCAM (#6721)] for 1 h at room temperature. Membranes were again washed three 268!
! 12!
times for 5 min followed by incubation in enhanced chemiluninescence reagent (BioRad, Herts, UK). 269!
A BioRad ChemiDoc (Herts, UK) was used to visualize and quantify protein expression. Phospho-270!
PKB was normalized to the corresponding total protein. Data are representative of 3 independent 271!
experiments carried out in duplicate. 272!
Membrane proteome  273!
Proteins associated with membranes were assessed using the SILAC proteomic method (38). C2C12 274!
myoblasts were grown in Dulbeccos’ modified eagles medium (DMEM) supplemented with 20% 275!
dialysed (10 kKDa) foetal bovine serum plus labelled amino acids lysine and arginine in a humidified 276!
atmosphere of 37°C and 5% CO2. Cells intended to act as the control group were grown in with 277!
unlabelled lysine and arginine (light), the EPA treatment group were grown in R6K4 media (l-278!
arginine-13C6 hydrochloride, l-lysine-4,4,5,5-d4 hydrochloride[medium]) while the DHA treatment 279!
group were grown with R10K8 containing media (l-arginine-13C6, 15N4 hydrochloride, l-lysine-280!
13C6,15N2 hydrochloride [Heavy]). The use of combined labelled arginine and lysine ensures that 281!
nearly all peptides will contain a label after tryptic digestion. Cells were allowed to grow for at least 6 282!
population doublings to ensure full incorporation of labelled amino acids. We observed that use of 283!
dialysed sera and labelled media did not affect doubling time, cell morphology or differentiation 284!
capacity. Upon reaching 90-100% confluence the media was replaced with DMEM containing 2% 285!
dialysed donor horse serum (10 kDa) to induce differentiation. After 3-4 days of differentiation, 286!
myotubes were treated with either control, 50µM EPA or 50 µM DHA for 72 hours. For membrane 287!
proteome analysis, membranes were isolated using the Thermo scientific Mem per plus protein 288!
membrane extraction kit. The membrane proteome was assessed by LC-MS/MS. 289!
Mass spectrometry 290!
The resulting peptides were fractionated using an Ultimate 3000 nanoHPLC system in line with an 291!
Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific).  In brief, peptides in 1% (vol/vol) 292!
formic acid were injected onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific). After 293!
washing with 0.5% (vol/vol) acetonitrile 0.1% (vol/vol) formic acid peptides were resolved on a 250 294!
mm × 75 µm Acclaim PepMap C18 reverse phase analytical column (Thermo Scientific) over a 150 295!
! 13!
min organic gradient, using 7  gradient segments (1-6% solvent B over 1min., 6-15% B over 58min., 296!
15-32%B over 58min., 32-40%B over 5min., 40-90%B over 1min., held at 90%B for 6min and then 297!
reduced to 1%B over 1min.) with a flow rate of 300 nl min−1.  Solvent A was 0.1% formic acid and 298!
Solvent B was aqueous 80% acetonitrile in 0.1% formic acid.  Peptides were ionized by nano-299!
electrospray ionization at 2.0 kV using a stainless steel emitter with an internal diameter of 30 µm 300!
(Thermo Scientific) and a capillary temperature of 275°C.  301!
All spectra were acquired using an Orbitrap Fusion Tribrid mass spectrometer controlled by Xcalibur 302!
2.1 software (Thermo Scientific) and operated in data-dependent acquisition mode.  FTMS1 spectra 303!
were collected at a resolution of 120 000 over a scan range (m/z) of 350-1550, with an automatic gain 304!
control (AGC) target of 300 000 and a max injection time of 100ms. Precursors were filtered using an 305!
Intensity Range of 1E4 to 1E20 and according to charge state (to include charge states 2-6) and with 306!
monoisotopic precursor selection. Previously interrogated precursors were excluded using a dynamic 307!
window (40s +/-10ppm). The MS2 precursors were isolated with a quadrupole mass filter set to a 308!
width of 1.4m/z. ITMS2 spectra were collected with an AGC target of 20 000, max injection time of 309!
40ms and CID collision energy of 35%. 310!
Quantification and bioinformatics analysis 311!
The raw mass spectrometric data files obtained for each experiment were collated into a single 312!
quantitated data set using MaxQuant (version 1.2.2.5) (10) and the Andromeda search engine software 313!
(11). Enzyme specificity was set to that of trypsin, allowing for cleavage N-terminal to proline 314!
residues and between aspartic acid and proline residues. Other parameters used were: (i) variable 315!
modifications, methionine oxidation, protein N-acetylation, gln ! pyro-glu, Phospho(STY); (ii) fixed 316!
modifications, cysteine carbamidomethylation; (iii) database: target-decoy human MaxQuant 317!
(ipi.HUMAN.v3.68); (iv) heavy labels: R6K4 and R10K8; (v) MS/MS tolerance: FTMS- 10ppm , 318!
ITMS- 0.6 Da; (vi) maximum peptide length, 6; (vii) maximum missed cleavages, 2; (viii) maximum 319!
of labeled amino acids, 3; and (ix) false discovery rate, 1%. Peptide ratios were calculated for each 320!
arginine- and/or lysine-containing peptide as the peak area of labeled arginine/lysine divided by the 321!
peak area of nonlabeled arginine/lysine for each single-scan mass spectrum. Peptide ratios for all 322!
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arginine- and lysine-containing peptides sequenced for each protein were averaged. Data is 323!
normalised using 1/median ratio value for each identified protein group per labelled sample. 324!
Statistics 325!
Statistical analyses were carried out in Graphpad Prism with ANOVA followed by Tukey’s HSD test. 326!
For FAME analyses data were assessed in R statistical packages and tested by t-test and corrected by 327!
false discovery rate. Statistical significance was determined with a p<0.05. The global lipidomic data 328!
sets were subjected to principal component analysis (PCA) and orthogonal projection latent structure-329!
discriminant analysis (OPLS-DA) with Pareto scaling using SIMCA-P v13.0 software (Umetrics, 330!
Umea, Sweden). The OPLS-DA models were validated by using the internal cross-validation 331!
function. Membrane protein abundance was considered altered if fold change was lower than 0.75 or 332!
greater than 1.25. Enrichment of biological processes was determined using gene ontology, using the 333!
whole genome of Mus musculus as a background reference list. 334!
  335!
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Results 336!
EPA and DHA substantially increase the abundance of omega-3 species but have differential 337!
effects on individual omega-3 fatty acids.  338!
After exposure to 50uM EPA or DHA for 72 hrs C2C12 myotubes were collected for FAME analysis 339!
to determine lipid profiles. EPA and DHA significantly increased total omega-3 fatty acid content 340!
from baseline values (EPA; 951 ± 81% p=0.0014, DHA; 750 ± 56% p=0.0009) with no significant 341!
difference detected between EPA and DHA treatment (p=0.115) (Figure 1). The changes in omega-3 342!
abundance are a result of differential shifts in specific omega-3 fatty acids caused by EPA or DHA 343!
treatment. The increase in omega-3 content by DHA is a result of accumulation of mainly DHA [22:6 344!
n-3, 3050% ± 310% (Figure 5)]. While, incubation of myotubes with EPA results in the accumulation 345!
of EPA [(20:5 n-3), 1630% ± 23.38] and DPA [(22:5 n-3), 1318% ± 199.8%] (Figure 5). These data 346!
suggest that EPA is elongated to DPA whilst DHA remains largely unmodified. 347!
EPA and DHA have differential effects on skeletal muscle glucose uptake.  348!
Insulin stimulated 2-deoxy-glucose (2DG) uptake was determined after 48 h in either EPA or DHA. 349!
EPA treatment significantly increased both basal and insulin stimulated 2DG uptake indicating that 350!
EPA treatment increases the capacity for glucose uptake (Figure 2A). DHA did not have any 351!
significant effects on 2DG uptake (Figure 2A). The observed changes in 2DG uptake did not appear 352!
to be related to any change in insulin stimulated PKB phosphorylation as phospho-blot analysis 353!
revealed that insulin stimulated PKB phosphorylation was the same between treatments and controls 354!
(Figure 2B). In addition EPA/DHA treatment did not appear to affect GLUT1 or GLUT4 expression 355!
(Figure 1C), nor did they appear to affect the expression of Hexokinase 1 or Hexokinase 2 (Figure 356!
1D). 357!
EPA and DHA treatment does not alter mitochondrial respiration. 358!
As no changes in glucose transporters were detected we next assessed whether changes in 359!
mitochondrial oxygen consumption may explain the increase in glucose uptake following EPA 360!
treatment. C2C12 myotubes were treated with 50uM EPA or DHA for 24 hours. Following treatment 361!
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multiple inhibitors/uncouplers (Oligomycin, FCCP, rotenone/anitmycin A) were used to probe various 362!
parameters of mitochondrial function using the seahorse XF mito stress test. A two way ANOVA 363!
found a significant interaction between oxygen consumption and inhibitor compound, indicating the 364!
successful manipulation of mitochondrial function (Figure 3A). However, fatty acid treatment did not 365!
lead to changes in cellular oxygen consumption on any parameter measured (Figure 3A). Consistent 366!
with the lack of changes in mitochondrial function, there were no alterations in the abundance of ATP 367!
synthase and UCQR2 (Complex V and Complex III respectively) (Figure 3B/C). 368!
EPA enhances protein accretion through a reduction in protein breakdown while DHA has a 369!
neutral effect 370!
After a 72 hour incubation with EPA or DHA, myotubes were collected in order to determine total 371!
protein content. When myotubes were incubated with EPA total protein content was enhanced while 372!
incubation with DHA had a neutral effect (Figure 4C). Protein balance is determined by the balance 373!
between synthesis and breakdown of proteins. Thus, the observed protein accretion may be reflected 374!
in changes in either protein synthesis or breakdown. In order to understand the mechanisms 375!
underlying the changes in protein content we directly assessed protein synthesis and breakdown and 376!
related signalling processes. Neither fatty acid had any effect on basal protein synthesis after a 24-377!
hour incubation (Figure 4A). Anabolic signalling assessed by the phosphorylation status of mTOR, 378!
P70S6K1 and 4E-BP1 were not different between groups, corresponding with lack of changes in 379!
protein synthesis (Figure 4E/F). EPA reduced protein breakdown compared to both the vehicle and 380!
DHA treatments (Figure 4B). No changes were detected in the level of ubiquitin tagged proteins 381!
(Figure 4D/F). 382!
EPA treatment differentially regulates DPA levels whilst DHA treatment differentially regulates 383!
arachidonic acid levels. As previously mentioned, incubation of C2C12 with 50 µM EPA or 50 µM 384!
DHA led to substantial cellular incorporation of total omega-3 fatty acids (Figure 1A). This was 385!
associated with the above mentioned physiological changes. In order to determine the potential 386!
mechanisms by which these effects occur we determined via FAME analysis the fatty acid changes 387!
responsible for the increase in total n-3 levels in the cells treated with EPA/DHA. In order to clearly 388!
! 17!
distinguish differential fatty acid shifts we presented the complete fatty acid profiles as fold change 389!
[(log2) Figure 5]. The most clearly differentiated fatty acid is DPA (22:5 n3) which demonstrates a 390!
significant 1318 ± 200% increase with EPA treatment whilst DHA treatment induces a 17.83 ± 391!
17.37% decrease in DPA content. Additionally there is a trend (p=0.06) for EPA treatment to increase 392!
the DHA content of the cells (37.11 ± 12.62%) suggesting that only a small proportion of the EPA is 393!
converted to DHA.  Surprisingly arachidonic acid (20:4 n6) was only significantly decreased by DHA 394!
treatment (-22.35 ± 3.174%) and remained unaffected by EPA treatment. Intriguingly we also 395!
observed that both EPA and DHA increased the content of the saturated fatty acid palmitate (PA 16:0) 396!
(Figure 5). In order to build a more complete picture of the impact of EPA and DHA on the lipidome 397!
we proceeded with a global lipidomics assessment. 398!
Global lipidomics reveals that EPA and DHA treatments induce substantial divergence in the 399!
lipidome. Lipid extracts of cells treated with BSA (control), EPA or DHA were analysed by LC-MS 400!
in positive and negative ion modes, processed and subjected to multivariate data analysis. PCA 401!
highlights any natural clustering or separation within a data set and thereby enables similarities or 402!
differences between study groups to be explored. The PCA scores plots of both the positive and 403!
negative ion data sets revealed that EPA and DHA supplementation caused a substantial divergence in 404!
the lipidome, effectively segregating control and treated cells (Fig. 6A and 6B). Having established 405!
the existence of clustering behaviour between the sample cohorts more powerful multivariate methods 406!
were used to characterise the specific lipid changes responsible for the observed shift in the lipidome 407!
of the EPA and DHA treated myotubes. The OPLS-DA scores plots and associated ‘S’ plots of the 408!
positive ion data are shown in Fig. 7A and 7B. The results indicated that many of the key 409!
discriminating lipids associated with EPA and DHA treatment were phospholipids and in particular 410!
molecular species of PC and PE.. In EPA treated cells elevations in PC and PE species containing 411!
both 20:5 and 22:5 fatty acids (in agreement with FAME analysis) were observed, whereas there were 412!
relative increases in the abundance of phospholipid species with a 22:6 fatty acid in DHA treated 413!
cells. The analysis also revealed that both EPA and DHA treatments also resulted in an elevation of 414!
PC 32:0, a saturated species. DHA was also found to be incorporated into a number of triglyceride 415!
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species (see supplemental). In order to fully understand the impact of EPA and DHA treatment we 416!
followed up these experiments through the targeted analysis of the myotube phospholipids.  417!
Targeted phospholipid analysis reveals that EPA and DHA increase the fraction of lipid species 418!
containing long chains and 5 or more double bonds at the expense of shorter chain, less 419!
saturated species. ESI-MS/MS was utilised to characterise the profiles of myocyte phospholipid 420!
classes. Representative mass spectra of PC and PE are shown in Figure 8A and 8B. The general 421!
trends (Figure 9) in both EPA and DHA were similar with the displacement of shorter chain in 422!
apparent preference for longer chain highly unsaturated fatty acids. However, the magnitude of 423!
change for these displacements was often higher with DHA. There was no evidence of alterations in 424!
the profile of sphingomyelin species in response to fatty acid treatments. ESI-MS/MS analysis of PS 425!
and PI was also performed however the low signal intensities of these lipids did not permit a robust 426!
quantification. Interestingly EPA and DHA supplementation led to a higher abundance of 427!
phospholipid species containing saturated fatty acids. For instance DHA induced an increase in PC 428!
(32:0) and lysophosphatidylethanolamine (LPE) (16:0), whilst EPA induced an increase in PC (32:0,) 429!
LPC (16:0), (18:0) and LPE (18:0). It is therefore evident that in spite of significant increases in 430!
saturated fatty acids in these EPA and DHA treatment still improve or maintain glucose uptake 431!
respectively.   432!
Altered composition of phospholipids is associated with altered membrane associated proteomic 433!
profiles. 434!
As the lipidomic remodelling indicated substantial changes induced by n-3 treatment in the membrane 435!
associated lipid species we carried out SILAC based proteomics profiling of the membrane fraction to 436!
assess if the lipid remodelling altered the proteins in the membrane fraction. Over 3000 proteins 437!
associated with the membrane compartment were identified in the SILAC screen. These results were 438!
filtered down to 625 proteins (see supplemental) with a coefficient of variance ≤ 5% to describe 439!
consistent changes in membrane abundance.  Proteins were considered enriched or reduced in the 440!
membrane with a fold change cut off of 0.25. Proteins similarly affected by EPA and DHA were 441!
removed from analysis. Proteins with altered abundance were then subject to gene ontology analysis 442!
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for biological processes (see supplemental). Membrane proteins altered by EPA were associated with 443!
protein folding (p = 4.76E-03). Additionally, these proteins were subjected to String analysis which 444!
revealed that these proteins were highly likely to interact with eachother (Figure 10B). EPA also 445!
increased Calumenin in the membrane fraction (1.34 fold).  Interestingly, Calumenin plays a role in 446!
calcium sensitive protein folding (49). DHA altered proteins associated with a number of processes, 447!
primarily related to oxidative metabolism and ribosomal formation (see table 1). Further examination 448!
of ribosomal proteins revealed that DHA induced the significant reduction in ribosomal proteins 449!
associated with both small and large subunits at the membrane (Figure 10C). Conversely, EPA 450!
induced a small increase in ribosomal proteins (Figure 10C). 451!
  452!
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Discussion 453!
This study is the first to carry out a comprehensive analysis of the lipidomic profiles of a skeletal 454!
muscle cell line in response to two differentially bioactive n-3 fatty acids. Furthermore, it is the first 455!
study, to our knowledge, to combine this with a profile of the membrane associated proteome. We 456!
clearly demonstrate the differential metabolic activities of EPA vs DHA in the C2C12 skeletal muscle 457!
cell line and provide data demonstrating the differential impact that EPA and DHA have on the 458!
skeletal muscle lipidome. Our data suggests that the bioactivity of EPA may be due to its preferential 459!
incorporation (and possibly elongation to DPA) into the phospholipid fraction where it substantially 460!
alters the long chain polyunsaturated fatty acid composition of major phospholipid classes. Likely 461!
secondary to the alterations in membrane associated phospholipids we see an altered membrane 462!
associated proteome. These changes in the membrane lipid-protein composition may be a key driver 463!
for the metabolic effects of n3 fatty acids. 464!
Similar to previous cell culture based studies (1, 21), we show that EPA has a positive effect on 465!
glucose uptake. Both basal and insulin stimulated muscle glucose uptake were improved by EPA but 466!
not DHA. The increase in glucose uptake appears to be independent of changes in PKB signalling as 467!
measured by phosphorylation status which suggests that enhanced proximal insulin and possibly PKB 468!
signalling are not part of the mechanism of action. Furthermore, there was no significant change to the 469!
expression of the glucose transporters GLUT1/4, hexokinase1/2 or the mitochondrial enzymes 470!
UQCRC2 and ATP-synthase. Nor was there any significant change in mitochondrial function as 471!
assessed by the mitochondrial stress test. These data are difficult to consolidate, however, we 472!
hypothesize that the mechanism of action of EPA on glucose uptake may be dependent less upon 473!
changes in protein expression and more dependent upon protein localisation perhaps improving the 474!
functional coupling of glucose metabolism enzymes.     475!
In addition to the EPA induced improvements in glucose uptake we also noted a significant 476!
improvement in protein accretion with EPA treatment, while DHA showed no significant effect. To 477!
determine the mechanism by which cells treated with EPA accumulate more protein we assessed 478!
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muscle protein synthesis and muscle protein breakdown. While Kamolrat et al (24) observed 479!
enhanced leucine stimulated MPS following EPA treatment, we detected no significant changes in  480!
basal muscle protein synthesis or the phosphorylation of anabolic signalling markers. Instead, we 481!
determined that the effect of EPA on protein accretion was likely driven by an ~10% reduction in 482!
muscle protein breakdown. Analysis of global ubiquitination via western blotting indicates that the 483!
reduction in muscle protein breakdown may not be driven by a change in the activity of the ubiquitin 484!
system. Rather, it may be driven by reduced lysosomal degradation (9). In saying that we must 485!
concede however, that a 10% reduction in ubiquitin driven protein breakdown would be challenging 486!
to detect via western blotting.  487!
In an effort to determine the molecular mechanism of action of EPA on skeletal muscle glucose 488!
uptake and protein accretion we tested the hypothesis that EPA and DHA treatments would induce 489!
significant lipid remodelling leading to remodelling of the cellular proteome. We found that while the 490!
total n-3 content was similar between treatments, EPA resulted in a larger variation in lipid species 491!
accumulating mainly as EPA and DPA and to a lesser extent DHA while DHA treatment mainly 492!
resulted in DHA accumulation with a decrease in DPA and a limited retro-conversion to EPA. The 493!
main differentially regulated fatty acids were DPA, increased in EPA and decreased in DHA, while 494!
only DHA decreased AA. Interestingly DPA accumulated to a similar extent as EPA [1630% (EPA) 495!
vs 1318% (DPA)], findings consistent with previous literature in other tissues (2, 26). Given that DPA 496!
increased to a similar extent to EPA we are unable to determine whether it is EPA or DPA that is the 497!
main driver behind the metabolic effects observed. These data suggest that upon intake into the cell 498!
EPA is elongated to DPA and to a lesser extent DHA. The elongation of EPA to DPA but not DHA 499!
may be explained by the differential affinities of the desaturases and elongases involved in fatty acid 500!
metabolism. In the n-3 pathway elovl2 catalyzes the conversion of EPA → DPA → 24:5 n-3, the 501!
precursor to DHA. However, increasing EPA concentrations is known to lower the saturation point in 502!
the conversion of DPA → 24:5 n-3 which may play a role the accumulation of DPA without being 503!
further metabolised to DHA (19). Our data indicate that one of the primary fates of EPA and DHA 504!
was incorporation into the phospholipid fraction. In the global lipidomics screen we found EPA or 505!
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DPA containing lipid species associated with the phospholipid pool whilst DHA containing species 506!
were often associated with the TAG pool whilst EPA containing species were rarely associated with 507!
the TAG pool (see supplemental spread sheet). Fatty acids in the TAG pool are stored in discrete lipid 508!
droplets and therefore may be less metabolically active than the phospholipids associated with the 509!
membranes. This differential incorporation into the various lipid pools may partially explain the 510!
beneficial metabolic effects of EPA.  511!
The potential relevance of DPA as a mediator of many of the physiological effects of n-3 512!
supplementation is beginning to be further understood. DPA more potently inhibits platelet 513!
aggregation than EPA or DHA (3) as well as more potently stimulating endothelial cell migration than 514!
EPA or DHA (25). In macrophages EPA is a known inhibitor of the cyclooxygenase pathway and 515!
elongation to DPA is an important factor in this inhibition (36). We would suggest that the elongation 516!
of EPA to DPA seen in our study may also have important physiological roles in the increase in 517!
skeletal muscle glucose uptake by EPA. As with the global lipidomic analysis we observed the 518!
incorporation of long chain PUFAs into phospholipid species mainly at the expense of specific SFAs 519!
and MUFAs, however some specific SFAs were increased by both EPA and DHA. We identified 520!
multiple differentially regulated phospholipid species across PE, PC, LPE and LPC classes. In the 521!
EPA treated group a number of species were enriched by long chain PUFAs with 5 or more double 522!
bonds in addition to a number of EPA or DPA containing phospholipids in the PC and PE, fractions In 523!
comparison, the DHA treated group increased the long chain PUFA containing phospholipids but did 524!
not increase or increase as much as EPA the content of species containing 22:5 or 40:5. Interestingly, 525!
with DHA treatment there was a trend for an increase in the palmitate containing lyso-PE content 526!
above that of control and EPA. Additionally, while it appears that many phospholipids containing 527!
saturated fatty acids are displaced in favour of polyunsaturated containing phospholipids we observe a 528!
rise in PC (32:0) with both EPA and DHA, which may reflect the rise in palmitate observed with 529!
FAME analysis. Incorporation of PUFAs into phospholipids is known to increase membrane fluidity 530!
and we speculate that this increase may be a compensatory mechanism to maintain a base level of 531!
membrane rigidity.  532!
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An attractive mechanism for the differential effects of EPA and DHA may lie in the reduced 533!
production of different inflammatory eicosanoids. However, only DHA reduced the total amount of 534!
AA. Additionally, the displacement of phospholipids alongside a lack of inflammatory stimulus 535!
suggests it is unlikely that this would mediate the metabolic differences seen in this model.  The G 536!
protein coupled receptor GPR120 has previously been identified as a general n-3 sensor in a number 537!
of tissues except skeletal muscle that elicits potent anti-inflammatory and consequently insulin 538!
sensitizing effects (37). To our knowledge no such receptor exists in skeletal muscle that can 539!
discriminate between EPA and DHA deeming it unlikely that the observed differential effects are 540!
mediated by EPA or DHA through specific receptor activated signalling.   541!
Phospholipid species are not merely inert structural components of cellular membranes and their 542!
various roles in intracellular processes are beginning to be further understood. PS and PE are related 543!
phospholipid species found predominantly in the inner membrane and contribute to the membrane 544!
targeting and activation and modification of protein kinases [as reviewed (51)]. It has also previously 545!
been seen that the lyso-PC, a hyrdrolyzed form of phospholipid, stimulated adipocyte glucose uptake 546!
in a manner dependent upon chain length and saturation of the acyl group (54). We observed an 547!
incorporation of long chain PUFAs (possibly EPA and DPA) into the PC, PS, PE and certain lyso-PL 548!
species and therefore cannot discount that the change in acyl chain length and unsaturation level alters 549!
the function of these PL species and leads to an increase in glucose uptake through a currently 550!
unknown mechanism. Because, the lipid composition of the membrane can alter the targeting of 551!
various proteins to the membrane (50, 51) we speculated that part of the mechanism of action of EPA 552!
might be via a change in the composition of the membrane associated proteome. To test this theory 553!
we carried out a 3 way SILAC experiment on the membrane fractions of cells treated with vehicle, 554!
EPA or DHA.   555!
Our SILAC experiment illustrated the proof of concept that the incorporation of EPA and DHA into 556!
phospholipid species was associated with the alteration of proteins interacting with the membrane 557!
compartment. There are a number of mechanisms by which proteins can bind to the membrane which 558!
are influenced by the fatty acid composition of the lipid bilayers (50, 51). Gene ontology analysis 559!
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indicated that proteins associated with protein folding at the membrane were overrepresented 560!
following EPA incorporation. There is experimental evidence that a number of the proteins identified 561!
with this process interact, as probed by the STRING database. Furthermore, analysis of ribosomal 562!
proteins indicated a small but significant shift of ribosomal proteins towards the membrane fraction in 563!
EPA treated cells. Since the endoplasmic reticulum is a membranous structure these data suggest that 564!
EPA is increasing the content of ribosomes at the ER. This shift in ribosomes towards the ER could 565!
lead to improved fidelity of protein production as the ER is key to protein quality control (15). We 566!
propose a mechanism in which protein folding is enhanced, thereby enhancing the fidelity with which 567!
proteins are synthesised thereby reducing protein breakdown leading to increased protein accretion. 568!
Further experimental work is needed to confirm this hypothesis since mis-folded proteins tend to be 569!
degraded by the ubiquitin-proteasome system (9) and our data indicated that global ubiquitination was 570!
not reduced by EPA. By comparison, DHA caused a striking reduction in the abundance of a number 571!
of ribosomal proteins with the membrane fraction. If future work confirms that total ribosomal content 572!
is unchanged with these conditions then these data would indicate an increase in cytosolic ribosomes. 573!
This differential shift in ribosomal compartmentalisation may indicate a shift in protein expression 574!
profiles. Proteins that enter the secretory pathways or integral membrane proteins are synthesised in 575!
the ER while other proteins are translated in the cytosolic ribosome pool (41).  576!
DHA also altered the abundance of proteins involved in ATP coupled proton transport and acetyl-577!
CoA metabolism. The proteins identified with ATP synthesis coupled transport were mainly 578!
downregulated proteins in the ATP synthase complex. This would be expected to manifest as a 579!
reduced ability to generate ATP yet no changes were observed in ATP synthase dependent oxygen 580!
consumption. The effects of DHA may not have been severe enough to observe at basal levels. 581!
Although maximal respiration is measured during the mito stress test, it is induced by uncoupling so 582!
may not be indicative of changes in ATP synthesis. Previous studies have observed that omega-3 fatty 583!
acids can alter mitochondrial function, altering ADP kinetics without altering maximal respiration 584!
(20). It remains to be seen if this reduction in ATP synthase proteins would alter the mitochondrial 585!
response to cellular stress or changing substrate availability. 586!
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In summary, we demonstrate that EPA and DHA display divergent metabolic activities in a skeletal 587!
muscle cell line, which may be partially mediated by differential remodelling of the lipidome. We 588!
speculate that the remodelling of the membrane-associated proteome is secondary to the changes 589!
observed in the saturation profile of the membrane-associated phospholipid species. Whilst the 590!
proteomic data did not reveal a mechanism for the effects of EPA on glucose uptake, our data support 591!
the proof of concept that a redistribution of the proteome may be responsible. Gene ontology analysis 592!
of the proteomic data indicate that the mechanism of action of EPA on protein metabolism may be 593!
driven by an improved fidelity with which proteins are synthesised. Based on the shifts in ribosomal 594!
proteins found in the membrane fractions future work should determine if EPA and DHA alter the 595!
transcript profiles in various ribosomal fractions. 596!
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Figure Legends 762!
Figure 1. EPA and DHA enhance n-3 content to a similar degree. C2C12 myotubes were incubated 763!
in either fatty acid free 2% BSA or fatty acid free 2% BSA pre-conjugated to 50 µM EPA or 50 µM 764!
DHA for 72hrs. Fatty acid analysis was carried out by FAME analysis (n=4 in duplicate) and data are 765!
presented as % change from BSA control grouped by fatty acid species; SFA – saturated fatty acids, 766!
MUFA – monounsaturated fatty acids, n-9 PUFA – omega-9 polyunsaturated fatty acids, n-6 PUFA – 767!
omega-6 polyunsaturated fatty acids, n-3 PUFA – omega-3 polyunsaturated fatty acids. 768!
Figure 2. EPA and DHA have differential effects on C2C12 glucose uptake independently of 769!
changes in PKB Thr308 phosphorylation or GLUT1/4 and Hexokinase1/2 expression. Glucose 770!
uptake was determined using a radiolabelled 2 Deoxy-glucose uptake assay (n=6 in duplicate) (A) and 771!
PKB Thr308 phosphorylation (n=4 in duplicate) (B) was determined using SDS-PAGE and phospho-772!
specific antibodies, the signal for which was normalised to t-PKB expression (representative blots are 773!
inset). GLUT1/4 expression (C) were normalised to t-eEF2 whilst Hexokinase1/2 expression (D) were 774!
normalised to α-tubulin. Bars not connected by the same letter are significantly different from each 775!
other (p<0.05). 776!
Figure 3. EPA and DHA treatment do not modulate mitochondrial function or mitochondrial 777!
protein expression. C2C12 myotubes were incubated in either fatty acid free 2% BSA or fatty acid 778!
free 2% BSA pre-conjugated to 50 µM EPA or 50 µM DHA for 48hrs. One set of myotubes was 779!
exposed to a mitochondrial stress test in the SeaHorse XFA and oxygen consumption was assessed 780!
(A). A parallel set of myotubes were collected for western blot analysis of mitochondrial protein 781!
expression with the mito-blot panel (B). Representative blots are shown in (C). 782!
Figure 4. EPA enhances protein accretion through a reduction in protein breakdown. A) Protein 783!
synthesis was measured by a L-[2,4,3H] phenylalanine incorporation assay following a 24 hr 784!
incubation with n-3 fatty acids (n=5 in duplicate) B) protein breakdown was assessed by the release of 785!
L-[2,4,3H] phenylalanine into culture media after 24hr treatment with  n-3 fatty acids (n=10, in 786!
duplicate) C) total protein content was assessed after a 72hr incubation with EPA or DHA (n=5, in 787!
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duplicate) D) Phosphorylation of proteins within the mTOR signalling pathway were assessed by 788!
western blotting after a 24 hr incubation with n-3 fatty acids (n=3 in duplicate) E) ubiquitination of 789!
proteins were assessed by western blotting after a 24hr incubation with fatty acids (n=3 in duplicate). 790!
# indicates significantly different from Veh and DHA, * indicates significantly different from 791!
corresponding control condition (p<0.05). 792!
Figure 5. Complete fatty acid profiles reveal a number of fatty acids differentially regulated by 793!
EPA and DHA. C2C12 myotubes were incubated in either fatty acid free 2% BSA or fatty acid free 794!
2% BSA pre-conjugated to 50 µM EPA or 50 µM DHA for 72hrs (n=4 in duplicate). Cells were 795!
pelleted and washed 3x using PBS with 2% fatty acid free BSA. Fatty acid analysis was carried out by 796!
FAME analysis. The fold change was determined from the BSA control condition and logged (log2). 797!
ND indicates non detectable, * indicates significant difference between EPA vs DHA (p<0.05).  798!
Figure 6. Global lipidomic analysis characterises shifts in lipid composition of C2C12 myotubes. 799!
Principal component analysis (PCA) scores plots of lipid profiles generated by LC-MS in (A) positive 800!
ion and (B) negative ion modes. Cultured cells were incubated with either fatty acid free 2% BSA 801!
(green circles), fatty acid free 2% BSA pre-conjugated to 50 µM EPA (red triangles) or 50 µM DHA 802!
(blue squares) for 72hrs. Global lipidomic analysis was performed on the cells and the data sets were 803!
subjected to PCA with Pareto scaling. Each point represents a single cell sample (n=6). The PCA 804!
revealed that the control, EPA and DHA groups could be discriminated on the basis of their lipid 805!
profiles. The control cells were found to cluster in one area of the scores plot whilst cells treated with 806!
EPA or DHA appeared in regions away from the controls indicating that were alterations in their lipid 807!
composition as a result of the fatty acid treatments.  808!
Figure 7. Lipidomic profiling reveals cellular lipid species containing EPA, DPA and DHA. 809!
Positive ion orthogonal partial least-squares discriminant analysis (OPLS-DA) for (A) BSA vs DHA 810!
and (B) BSA vs EPA (n=6). Green circles indicate BSA treated C2C12 myotubes; blue squares indicate 811!
DHA treated C2C12 myotubes and red triangles indicate EPA treated C2C12 myotubes. The OPLS-DA 812!
scores plots indicated that EPA and DHA groups had distinct lipid profiles compared to the controls. 813!
In order to determine the lipids responsible for the inter-class differences associated S-plots of 814!
! 32!
covariance versus the correlation were generated.!Each point in the S-plots represents a lipid detected 815!
in the LC-MS analysis with the lipids at the top and bottom of the plots showing the greatest changes. 816!
The analysis revealed that there was a relative increase in the abundance of lipid species containing 817!
20:5, 22:5 or 22:6 fatty acids in EPA and DHA treated cells respectively. 818!
 819!
Figure 8. Targeted phospholipid analysis indicates preferential incorporation of long chain 820!
polyunsaturated fatty acids into specific phospholipid classes. C2C12 myotubes were solvent 821!
extracted and molecular species of (A) phosphatidylcholine and (B) phosphatidylethanolamines were 822!
detected by ESI-MS/MS in positive-ion mode by means of a precursor ion scan for m/z 184 and a 823!
neutral loss scan of m/z 141 respectively. 824!
Figure 9. Targeted phospholipid analysis presented as % abundance for PC, PE, LPC and LPE 825!
species. C2C12 myotubes were solvent extracted and molecular species of (A) lyso-826!
phosphatidylcholine, (B) phosphatidylcholine, (C) lyso-phosphatidylethanolamine and (D) 827!
phosphatidylethanolamine were detected by ESI-MS/MS in positive-ion mode by means of a 828!
precursor ion scan for m/z 184 and a neutral loss scan of m/z 141 respectively. Data are presented as 829!
% abundance ± SEM. Bars not connected by the same letter are significantly different from one 830!
another (p<0.05). 831!
Figure 10. Membrane associated proteomics reveals protein folding machinery and ribosomal 832!
proteins differentially shift to the membrane in response to EPA treatment. C2C12 myotubes were 833!
incubated in SILAC media for 7 doublings followed by plating and differentiation for 72hrs in SILAC 834!
differentiation media. Following differentiation myotubes were incubated in either fatty acid free 2% 835!
BSA or fatty acid free 2% BSA pre-conjugated to 50 µM EPA or 50 µM DHA for 72hrs (n=3 in 836!
duplicate). Cells were collected and fractionated, the membrane fraction was then submitted to 837!
proteomics analysis. (A) Venne diagram illustrating the number of proteins found to be changed in the 838!
membrane fraction in response to EPA/DHA. (B) String diagram illustrating the interactions between 839!
the proteins identified from the GO analysis as being involved in ‘protein folding.’ (C) Fold change in 840!
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ribosomal proteins in the membrane fraction in response to EPA/DHA. * indicates a significant fold 841!
change from control (p<0.05). All differences between EPA and DHA were significant. 842!
 843!
 844!
 845!
 846!
 847!
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